Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
相关临床试验
167
151 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
151
90.4%
已完成
12
7.2%
Unknown
4
2.4%
暂无批准数据
- Arkansas AG Tim Griffin filed a lawsuit against 22 entities, including 13 major drug manufacturers, alleging illegal limits on 340B prescription drug discounts. - The lawsuit accuses companies including Pfizer, Johnson & Johnson, Eli Lilly, and Novo Nordisk of violating Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act. - Griffin cited over 300,000 instances of allegedly violative conduct, with the state seeking civil penalties under the Arkansas Deceptive Trade Practices Act. - The legal action follows a 2024 U.S. Supreme Court loss for PhRMA, which had challenged the Arkansas law as unconstitutional on behalf of several manufacturers.
- Daiichi Sankyo has dosed the first patient in a phase 1/2 trial evaluating DS3790, a potential first-in-class CD37-directed antibody drug conjugate for relapsed or refractory B-cell non-Hodgkin lymphoma. - DS3790 represents the company's first DXd ADC in hematology, targeting CD37, a transmembrane protein overexpressed on malignant B-cells with no currently approved therapies. - The multicenter trial will enroll approximately 420 patients globally to assess safety and efficacy, with plans to evaluate both monotherapy and combination approaches. - B-cell non-Hodgkin lymphoma accounts for over 85% of all non-Hodgkin lymphoma cases, with more than 604,000 cases diagnosed globally in 2021.
- Merck has entered into a $700 million funding agreement with Blackstone Life Sciences to support development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate targeting TROP2. - The ADC is currently being evaluated in 15 global Phase 3 clinical trials across six tumor types, including breast, endometrial, and lung cancers. - Blackstone will receive low-to-mid single-digit royalties on net sales contingent upon U.S. regulatory approval for first-line triple-negative breast cancer treatment. - Sac-TMT features a novel drug-to-antibody ratio of 7.4 and targets TROP2, a protein highly expressed in epithelial-derived tumors that promotes proliferation and metastasis.
- Researchers at Purdue University and Merck have developed a patent-pending Raman spectroscopy-based tool that monitors vaccine quality in real-time during production, delivering results in 30 seconds or less. - The tool successfully detected human cytomegalovirus particles at industrially relevant concentrations and flow rates, representing the first reported Raman spectroscopy system of this type for CMV detection. - Unlike current offline testing methods that require sample removal from production lines, this online monitoring system operates continuously during manufacturing, potentially saving time and money in vaccine production. - The technology supports continuous manufacturing processes and could be adapted for monitoring other vaccine types and viral particles in future applications.
- Proxygen, a leader in molecular glue degrader discovery, has announced a strategic research collaboration with EPFL to integrate AI-driven computational design with high-throughput screening platforms. - The partnership combines Proxygen's validated glue degrader discovery platform with Professor Bruno Correia's pioneering work in AI and structural modeling for protein design and therapeutic discovery. - The collaboration aims to systematically predict and validate neosubstrate-ligase interactions and design chemical matter capable of inducing targeted protein degradation across previously inaccessible target space. - This integrated approach is expected to accelerate glue degrader development with greater precision and scale, building on Proxygen's existing partnerships with major pharmaceutical companies including Merck KGaA and Merck & Co Inc.
- A comprehensive 2025 market report analyzes the global clinical trial landscape for mycosis fungoides, providing insights into trial distribution across regions and phases. - Major pharmaceutical companies including Pfizer, Bristol-Myers Squibb, Johnson & Johnson, and Novartis are actively participating in mycosis fungoides therapeutic development. - Recent clinical developments include Innate Pharma's durable responses with lacutamab and BioInvent's FDA Fast Track designation for BI-1808 in cutaneous T-cell lymphoma treatment. - The report covers enrollment trends over five years and provides strategic analysis for investment decisions in this rare cancer indication.
- A global review of dengue fever clinical trials reveals ongoing research across multiple regions and countries, with a focus on G7 and E7 nations. - The trials cover various phases, assessing different endpoints and involving diverse sponsor types, including pharmaceutical companies and research institutions. - Key players like Sanofi, Takeda, and GSK are actively participating in the development of dengue fever therapeutics and preventive measures. - Recent news highlights advancements and setbacks in dengue fever drug development, such as ISLA-101's Phase 2a results and Johnson & Johnson discontinuing a Phase 2 study.
- Merck's subcutaneous Keytruda, combined with chemotherapy, demonstrated non-inferiority to intravenous Keytruda plus chemotherapy in treating metastatic non-small cell lung cancer (NSCLC). - The Phase 3 study utilized Alteogen's berahyaluronidase alfa to enhance subcutaneous Keytruda permeation, showing positive results in first-line treatment. - This new formulation of Keytruda offers a potential alternative administration route for patients with various cancers, including melanoma and Hodgkin lymphoma.
• The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents. • Breast cancer research is also thriving, with over 100 companies exploring 120+ new drugs, such as antibody-drug conjugates and PARP inhibitors, in clinical trials. • Recent FDA actions, including Fast Track and Breakthrough Therapy designations, highlight the potential of emerging therapies for both renal and breast cancer. • Advances in diagnostics, such as PET imaging agents for clear cell renal cell carcinoma, are also contributing to improved management of these diseases.
